A Weekly Advocacy Message from Mary Woolley: Special early short edition this week

researchamerica

Dear Research Advocate:

I am sending out my letter early this week so that you can plan now, if you are not able to be with us in person tomorrow in Washington, to join us electronically for our National Health Research Forum. With the theme of ’€œStraight Talk,’€ our first-rate panelists will speak candidly about where our medical and health ecosystem is headed today ’€” what the possibilities are, if we give research and innovation every chance to succeed ’€” and what the policy and funding challenges are as we go forward. We thank Lilly, our lead sponsor; all our additional sponsors; and WebMD for live-streaming the event on their website at www.webmd.com/researchforum.

On the funding front, Congress may soon consider a simple, short-term continuing resolution (CR) to fund the government at levels slightly lower than the current FY13 level (that means including the sequestration hit), lasting until mid-December. There are no riders or mandates that affect NIH ’€” or any other agency for that matter. In the end, it’€™s likely that this CR will pass both chambers. But the fight to end sequestration continues, and an action opportunity may present itself with discussions spurred by the debt limit. We are planning our advocacy accordingly and will keep you in the loop.

Finally, I’€™d like to extend warm congratulations to the 2013 Albert and Mary Lasker Foundation award winners. These impressive scientists and philanthropists have worked tirelessly to advance basic and clinical medical research and ensure that research reaches those in need. These prestigious awards are well-deserved.

Sincerely,

Mary Woolley

Post ID: 
1548

Add comment

Plain text

  • No HTML tags allowed.
  • Adds node titles to internal links found in content (as HTML "title" attribute).
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
The capabilities are enormous, a little bit of research can pay off quite a bit in the long run.
Paul D’ Addario, retinitis pigmentosa patient